Deep Learning-Based Denoising Enables High-Quality, Fully Diagnostic Neuroradiological Trauma CT at 25% Radiation Dose.

Rationale And Objectives: Traumatic neuroradiological emergencies necessitate rapid and accurate diagnosis, often relying on computed tomography (CT). However, the associated ionizing radiation poses long-term risks. Modern artificial intelligence reconstruction algorithms have shown promise in reducing radiation dose while maintaining image quality.

Bactericidal/permeability-increasing protein instructs dendritic cells to elicit Th22 cell response.

Neutrophil-derived bactericidal/permeability-increasing protein (BPI) is known for its bactericidal activity against gram-negative bacteria and neutralization of lipopolysaccharide. Here, we define BPI as a potent activator of murine dendritic cells (DCs). As shown in GM-CSF-cultured, bone-marrow-derived cells (BMDCs), BPI induces a distinct stimulation profile including IL-2, IL-6, and tumor necrosis factor expression.

Diagnosis of Primary Hypophysitis in Germany.

Context: Representative data on diagnostic findings in primary hypophysitis (PrHy) are scarce.

Objective: The objective of the study was to collate consistent data on clinical features in a large series of patients with PrHy. Another objective was to gain information on current practice in a diagnostic work-up.

Treatment of Primary Hypophysitis in Germany.

Context: The best treatment of primary hypophysitis (PrHy) is a matter of debate.

Objective: Our main objective was to analyze the treatment practice for PrHy in Germany and to compare the outcome of the main treatment options.

Design: The Pituitary Working Group of the German Society of Endocrinology conducted a nationwide retrospective cross-sectional cohort study.

Evidence-based medicine works best when there is evidence: challenges in palliative medicine when randomized controlled trials are not possible.

Randomized controlled trials provide the best evidence for the safety and effectiveness of interventions. However, the reliance on this study design as the only criterion for credible evidence is not possible in all areas of palliative medicine. Although we must exercise caution in making definitive claims from uncontrolled trial data, limitations in performing controlled trials should neither preclude the use of findings from well-designed nonrandomized controlled trials nor, more importantly, deprive patients of potentially effective treatments.